_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
HYMPAVZI’s safety profile was generally favorable
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
